other material
confidence high
sentiment positive
materiality 0.65
SAB Biotherapeutics reports positive GLP tox study for SAB-142; IND submission planned
SAB Biotherapeutics, Inc.
- SAB-142 well tolerated in GLP tox study; NOAEL 10 mg/kg (highest dose).
- SAB-142 modulates key T-cell subsets similarly to rabbit ATG in vivo, confirming mechanism.
- Plans to submit IND for SAB-142 to FDA and initiate Phase 1 trial in coming months.
- Over 8.4M people affected by T1D worldwide; only one disease-modifying treatment available.